ANI Net Income From Continuing Ops vs Net Income Analysis
ANIP Stock | USD 61.43 2.34 3.67% |
ANI Pharmaceuticals financial indicator trend analysis is way more than just evaluating ANI Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether ANI Pharmaceuticals is a good investment. Please check the relationship between ANI Pharmaceuticals Net Income From Continuing Ops and its Net Income accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.
Net Income From Continuing Ops vs Net Income
Net Income From Continuing Ops vs Net Income Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of ANI Pharmaceuticals Net Income From Continuing Ops account and Net Income. At this time, the significance of the direction appears to have very strong relationship.
The correlation between ANI Pharmaceuticals' Net Income From Continuing Ops and Net Income is 0.89. Overlapping area represents the amount of variation of Net Income From Continuing Ops that can explain the historical movement of Net Income in the same time period over historical financial statements of ANI Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of ANI Pharmaceuticals' Net Income From Continuing Ops and Net Income is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Income From Continuing Ops of ANI Pharmaceuticals are associated (or correlated) with its Net Income. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Income has no effect on the direction of Net Income From Continuing Ops i.e., ANI Pharmaceuticals' Net Income From Continuing Ops and Net Income go up and down completely randomly.
Correlation Coefficient | 0.89 |
Relationship Direction | Positive |
Relationship Strength | Strong |
Net Income From Continuing Ops
Net Income
Net income is one of the most important fundamental items in finance. It plays a large role in ANI Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of ANI Pharmaceuticals operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Most indicators from ANI Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into ANI Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.As of 05/18/2024, Selling General Administrative is likely to grow to about 157.9 M, while Discontinued Operations is likely to drop slightly above 156 K.
2021 | 2022 | 2023 | 2024 (projected) | Gross Profit | 115.5M | 177.6M | 245.5M | 257.8M | Total Revenue | 216.1M | 316.4M | 486.8M | 511.2M |
ANI Pharmaceuticals fundamental ratios Correlations
Click cells to compare fundamentals
ANI Pharmaceuticals Account Relationship Matchups
High Positive Relationship
High Negative Relationship
ANI Pharmaceuticals fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 456.8M | 461.2M | 771.6M | 760.1M | 904.4M | 949.6M | |
Other Current Liab | 36.7M | 54.0M | 63.6M | 69.3M | 99.8M | 104.8M | |
Total Current Liabilities | 61.7M | 78.6M | 87.5M | 99.4M | 145.5M | 152.8M | |
Total Stockholder Equity | 212.8M | 195.7M | 358.7M | 338.5M | 432.7M | 454.4M | |
Property Plant And Equipment Net | 40.6M | 41.3M | 52.7M | 43.2M | 44.6M | 46.8M | |
Net Debt | 123.4M | 177.8M | 187.1M | 238.3M | 94.2M | 98.9M | |
Retained Earnings | 17.6M | (5.0M) | (47.8M) | (97.3M) | (80.1M) | (84.1M) | |
Accounts Payable | 14.6M | 11.3M | 23.0M | 29.3M | 36.7M | 38.5M | |
Cash | 62.3M | 7.9M | 100.3M | 48.2M | 221.1M | 232.2M | |
Non Current Assets Total | 269.1M | 290.9M | 449.8M | 415.8M | 384.8M | 404.0M | |
Cash And Short Term Investments | 62.3M | 7.9M | 100.3M | 48.2M | 221.1M | 232.2M | |
Common Stock Shares Outstanding | 12.0M | 12.0M | 12.6M | 16.3M | 18.2M | 19.1M | |
Liabilities And Stockholders Equity | 456.8M | 461.2M | 771.6M | 760.1M | 904.4M | 949.6M | |
Other Current Assets | 5.1M | 5.9M | 11.3M | 8.4M | 25.2M | 26.5M | |
Total Liab | 244.0M | 265.5M | 412.9M | 421.5M | 471.7M | 495.3M | |
Property Plant And Equipment Gross | 40.6M | 41.3M | 75.6M | 76.0M | 77.5M | 81.4M | |
Total Current Assets | 187.7M | 170.3M | 321.8M | 344.3M | 519.6M | 545.6M | |
Other Stockholder Equity | 200.1M | 212.1M | 384.7M | 398.8M | 479.2M | 503.1M | |
Accumulated Other Comprehensive Income | (4.9M) | (11.4M) | (3.1M) | 12.2M | 8.9M | 9.3M | |
Short Long Term Debt Total | 185.7M | 185.7M | 287.4M | 286.5M | 315.3M | 331.1M | |
Short Term Debt | 115.7M | 9.9M | 13.2M | 850K | 977.5K | 928.6K | |
Current Deferred Revenue | 451K | 80K | 87K | 8.2M | 9.4M | 9.9M | |
Non Currrent Assets Other | 1.2M | 802K | 2.2M | 2.6M | 6.1M | 6.4M | |
Non Current Liabilities Total | 182.3M | 186.9M | 325.3M | 322.1M | 326.2M | 342.5M | |
Net Receivables | 72.1M | 95.8M | 128.5M | 165.4M | 162.1M | 170.2M | |
Net Tangible Assets | 28.8M | 3.6M | 36.7M | 58.7M | 52.8M | 55.5M | |
Other Assets | 44.6M | 57.5M | 75.1M | 92.7M | 106.6M | 112.0M | |
Long Term Debt | 175.8M | 172.4M | 286.5M | 285.7M | 284.8M | 149.2M | |
Retained Earnings Total Equity | 17.6M | (5.0M) | (47.8M) | (97.3M) | (111.9M) | (117.5M) | |
Inventory | 48.2M | 60.8M | 81.7M | 105.4M | 111.2M | 116.8M | |
Deferred Long Term Liab | 1.5M | 800K | 500K | 600K | 690K | 458.1K | |
Intangible Assets | 180.4M | 188.5M | 294.1M | 251.6M | 209.0M | 156.5M | |
Property Plant Equipment | 40.6M | 41.3M | 52.7M | 43.2M | 49.7M | 52.2M | |
Capital Surpluse | 200.8M | 214.4M | 387.8M | 403.9M | 464.5M | 237.5M | |
Other Liab | 7K | 201K | 31.0M | 35.1M | 40.3M | 42.3M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Trending Equities to better understand how to build diversified portfolios, which includes a position in ANI Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in ANI Stock, please use our How to Invest in ANI Pharmaceuticals guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.
Complementary Tools for ANI Stock analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |
Is ANI Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of ANI Pharmaceuticals. If investors know ANI will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about ANI Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 13.824 | Earnings Share 1.61 | Revenue Per Share 27.705 | Quarterly Revenue Growth 0.287 | Return On Assets 0.0391 |
The market value of ANI Pharmaceuticals is measured differently than its book value, which is the value of ANI that is recorded on the company's balance sheet. Investors also form their own opinion of ANI Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is ANI Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because ANI Pharmaceuticals' market value can be influenced by many factors that don't directly affect ANI Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between ANI Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if ANI Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ANI Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.